Tonix Pharmaceuticals (NASDAQ:TNXP) Shares Up 54.5% – What’s Next?

Shares of Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) traded up 54.5% during mid-day trading on Thursday . The stock traded as high as $16.95 and last traded at $16.93. 6,687,768 shares were traded during trading, an increase of 1,096% from the average session volume of 559,142 shares. The stock had previously closed at $10.96.

Analyst Ratings Changes

Separately, StockNews.com started coverage on Tonix Pharmaceuticals in a research report on Monday, February 10th. They set a “sell” rating on the stock.

Tonix Pharmaceuticals Trading Down 11.0 %

The business’s 50-day moving average price is $21.65 and its 200-day moving average price is $21.02. The firm has a market capitalization of $24.33 million, a PE ratio of 0.00 and a beta of 2.23. The company has a debt-to-equity ratio of 0.07, a current ratio of 3.33 and a quick ratio of 2.81.

Institutional Investors Weigh In On Tonix Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Geode Capital Management LLC increased its position in Tonix Pharmaceuticals by 1,600.1% in the 4th quarter. Geode Capital Management LLC now owns 1,971,894 shares of the company’s stock valued at $650,000 after acquiring an additional 1,855,907 shares during the period. Jane Street Group LLC increased its holdings in shares of Tonix Pharmaceuticals by 5,932.3% in the fourth quarter. Jane Street Group LLC now owns 1,662,682 shares of the company’s stock valued at $548,000 after purchasing an additional 1,635,119 shares during the period. Point72 Asset Management L.P. purchased a new stake in shares of Tonix Pharmaceuticals during the fourth quarter worth approximately $526,000. Northern Trust Corp acquired a new stake in shares of Tonix Pharmaceuticals during the fourth quarter worth $162,000. Finally, PFG Investments LLC purchased a new position in Tonix Pharmaceuticals in the 4th quarter valued at $72,000. 82.26% of the stock is owned by hedge funds and other institutional investors.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.